Open an account

TherapeuticsMD

TXMD · NASDAQ

$1.88+$0.02 (+1.08%)TodayMarket closed ·
Prev close $1.86

About TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Employees
1
Headquarters
Boca Raton, Florida
Listed
Jan 31, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
therapeuticsmd.com

TXMD key statistics

Market cap
21.76M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
24.05K
Volume
13.48K
Open price
$1.91
High today
$1.91
Low today
$1.84
52 Week high
$2.95
52 Week low
$1.08

TherapeuticsMD (TXMD) at a glance

TherapeuticsMD (TXMD) last traded at $1.88, with a market cap of 21.76M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.84 and $1.91. The current price is 2.2% above the day's low and 1.6% below its high.

Volume so far is 13.48K shares, below the average of 24.05K shares a day.

Over the past year TherapeuticsMD has ranged from $1.08 to $2.95, and now sits 43% of the way up that range.

TherapeuticsMD met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY23 it reported -$0.13 per share against an estimate of -$0.051.

TXMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 663.2% on average.

  1. Q4 FY21: reported -$5.00 per share against an estimate of -$3.91
  2. Q1 FY22: reported -$5.69 per share against an estimate of -$4.08
  3. Q2 FY22: reported $12.39 per share against an estimate of -$3.10
  4. Q3 FY22: reported -$3.13 per share against an estimate of -$0.5814
  5. Q4 FY22: reported $8.23 per share against an estimate of -$1.13
  6. Q1 FY23: reported -$0.37 per share against an estimate of $0.0612
  7. Q2 FY23: reported -$0.24 per share against an estimate of -$0.0714
  8. Q3 FY23: reported -$0.13 per share against an estimate of -$0.051

TXMD news

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    TherapeuticsMD Announces First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Full Year 2025 Financial Results

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Third Quarter 2025 Financial Results

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Second Quarter 2025 Financial Results

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Full Year 2024 Financial Results

  • Press releaseBusiness Wire

    TherapeuticsMD Announces Third Quarter 2024 Financial Results

Similar companies

Companies in the same industry as TherapeuticsMD

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.